Exelixis insiders dump $36.3 M in shares as buy activity stalls

The most striking metric from Exelixis’ insider ledger is the buy‑to‑sell ratio of 0.07x for the trailing year, a level that falls well below the 0.2x threshold commonly used to flag heavy insider selling. Twenty‑eight sell transactions totaling $36,290,425 dwarf the two buy transactions that together amount to $2,374,470. The disparity is not a fleeting blip; it spans multiple quarters and involves twelve distinct insiders, indicating a sustained pattern rather than isolated events.

Directors account for the bulk of the activity, executing two purchases but sixteen sales that sum to $21,146,438. The most sizable single sale came from Director Jack L. Wyszomierski, who off‑loaded 99,574 shares for $4,382,252 on February 18, 2026. Close behind, Director Stelios Papadopoulos sold 100,000 shares for $4,355,000 in November 2025. Both transactions occurred well above the average daily volume, underscoring a willingness among board members to liquidate sizable positions.

Senior executives also contributed materially to the outflow. Vice President/ Senior Vice President/ Executive Vice President Patrick J. Haley sold 64,778 shares for $2,817,843 on February 17, 2026, while fellow EVP Dana Aftab disposed of 47,918 shares for $2,132,351 a week later. The CFO’s two sales, totaling $2,810,998, further reinforce the pattern of upper‑management divestment. Although some of these trades may be linked to scheduled equity compensation or tax planning, the concentration of sales within a narrow time frame—particularly the February 2026 cluster where five insiders sold more than $10 million combined—exceeds the typical routine and aligns with the analyst‑defined “cluster selling” signal.

From a market perspective, Exelixis shares sit at $49.84, near the 90th percentile of their 52‑week range, and the stock’s RSI of 66 indicates modest upward momentum. Yet the YTD return of 13.7% has not deterred insiders from reducing exposure. The timing of the largest sell months—May 2025 ($19.9 million) and February 2026 ($20.6 million)—coincides with periods of elevated price performance, suggesting that insiders may be capitalizing on recent gains.

While insider selling alone does not dictate future price direction, the scale, repeat participation of directors, and involvement of senior executives collectively send a cautionary signal. Investors should weigh this insider disposition against the company’s fundamentals and broader market trends before adjusting exposure to Exelixis.